Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

333.78 +3.52 (+1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 425,688
Open 328.82
Bid (Size) 327.23 (1)
Ask (Size) 344.00 (2)
Prev. Close 330.26
Today's Range 327.98 - 336.63
52wk Range 208.62 - 343.98
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace

Performance

YTD
+46.81%
+46.81%
1 Month
+1.99%
+1.99%
3 Month
+26.27%
+26.27%
6 Month
+54.35%
+54.35%
1 Year
+43.09%
+43.09%

More News

Read More
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
United Therapeutics Stock Skids On Mixed Second-Quarter Results
Via Investor's Business Daily
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
The 3 Best 3D Bioprinting Stocks to Buy Now
Via InvestorPlace
Navigating 9 Analyst Ratings For United Therapeutics
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
Via Benzinga
Unveiling 6 Analyst Insights On United Therapeutics
Via Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
From United Therapeutics Corporation
Via Business Wire
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
Via InvestorPlace
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
3 Undervalued Stocks on Track to Double (or More) by 2028
Via InvestorPlace
Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans.
Via The Motley Fool
Topics ETFs
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses
Via Talk Markets
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.